About Us

Our History

WuXi PharmaTech was registered in the city of Wuxi, Jiangsu and operated in Shanghai
WuXi started synthetic chemistry services
WuXi started manufacturing process development services
WuXi started manufacturing services for research and development
WuXi started bio-analytical services
WuXi started antibody discovery and process development services
WuXi started toxicology and formulation services
The Tianjin site of WuXi was put into operation and it was among the leading R&D bases of chemical medicines in China then
WuXi PharmaTech traded on the New York Stock Exchange under the ticker symbol "NYSE:WX"
WuXi set up "Life Science and Chemistry Awards", aiming to stimulate early-stage innovation and promote excellence in life sciences and clinical research
WuXi PharmaTech acquired AppTec Laboratory Services, with locations in Minnesota, Pennsylvania and Georgia. The Company has been renamed WuXi AppTec since then.
WuXi opened a toxicology facility in Suzhou, which became the most important base of toxicology services
SynTheAll Pharmaceutical (STA) opened a large-scale manufacturing facility in Jinshan District, Shanghai
WuXi acquired Medkey, expanding to clinical development and registration services
The R&D and manufacturing site in the city of Wuxi was put into operation
Wuhan site was put into operation, and it became the key of WuXi's strategic network in central and western China
WuXi AppTec opened a new facility in Philadelphia, Pennsylvania, strengthening R&D and production services of CAR-T therapies and other immunotherapies
WuXi Laboratory Testing Division expanded with acquisition of XenoBiotic Laboratories in Plainsboro, New Jersey, bolstering LTD's bioanalytical and DMPK/ADME services for U.S. customers
SynTheAll Pharmaceutical (STA) listed its shares on the New Third Board
WuXi launched medical device testing services in China
WuXi acquired Crelux, enhancing WuXi's structure-based drug discovery capabilities in Europe
STA began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou
WuXi set up Advanced Therapy Unit in Philadelphia, Pennsylvania, enhancing U.S.-based cell and gene therapies
WuXi acquired HD Biosciences in San Diego, California, strengthening U.S. biology R&D capacity and capability
WuXi acquired ResearchPoint Global in Austin, Texas, expanding U.S. clinical research capabilities
WuXi built up its Life Science Industry Park in Chengdu
WuXi AppTec announced listing of Initial Public Offering of Common Stock on the Shanghai Stock Exchange (stock code: 603259.SH)
WuXi AppTec listed H shares on the Hong Kong Stock Exchange (stock code: 2359.HK)
The first WuXi Healthcare Forum held in Shanghai
WuXi AppTec acquired Pharmapace in San Diego, California, to enhance biometrics services for clinical development